Feature image

What's New

Atomoxetine and the possible risk of gynaecomastia

Medsafe has published a new monitoring communication highlighting a potential risk of gynaecomastia with atomoxetine. Healthcare professionals and consumers are encouraged to report any cases of gynaecomastia suspected to be associated with atomoxetine use. Anyone can submit a report.

Go to the monitoring communication

News and Events

Date Type Title
7/1/2026NoticesNotice of Medsafe Office Closure Christmas/New Year 2025/2026
23/12/2025CommitteesMedicines Classification Committee - Dates and Deadlines
23/12/2025CommitteesMinutes of the 75th meeting of the Medicines Classification Committee - 19 November 2025
23/12/2025CommitteesMedicines Classification Committee Vacancies
15/12/2025Alert CommunicationAmended legislation about medicines that can impair driving
15/12/2025Monitoring CommunicationM² Logo Atomoxetine and the possible risk of gynaecomastia
8/12/2025ConsultationOutcome on Proposed updates to the Guideline on the Regulation of Therapeutic Products in New Zealand: Bioequivalence of medicines
8/12/2025ComplianceExemption for advertising unapproved medicines at medical conferences
4/12/2025PublicationsPrescriber Update Vol. 46. No. 4 - December 2025
3/12/2025Monitoring CommunicationFurther Update - Estradot (estradiol) transdermal patches: reports of quality and efficacy concerns
28/11/2025Alert CommunicationRecall of FreeStyle Libre 3 Plus CGM sensors (some batches only)
11/11/2025Monitoring CommunicationFurther Update - Estradot (estradiol) transdermal patches: reports of quality and efficacy concerns
5/11/2025Monitoring CommunicationUpdate - Estradot (estradiol) transdermal patches: reports of quality and efficacy concerns
3/11/2025Media Release#MedSafetyWeek 2025 Media Release